Adaptive Biotechnologies (ADPT) Cost of Revenue (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Cost of Revenue data on file, last reported at $18.7 million in Q1 2026.

• Quarterly Cost of Revenue rose 10.18% year-over-year to $18.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.1 million (down 7.97% YoY) and the FY2025 annual result came in at $71.4 million, down 15.81% from the prior year.
• Cost of Revenue climbed to $18.7 million in Q1 2026 per ADPT's latest filing, from $18.2 million in the prior quarter.
• The five-year high for Cost of Revenue was $26.1 million in Q1 2022, with the low at $8.9 million in Q4 2023.
• Average Cost of Revenue over 5 years is $19.2 million, with a median of $18.7 million recorded in 2026.
• Year-over-year, Cost of Revenue plunged 62.56% in 2023 and jumped 142.96% in 2024.
• Adaptive Biotechnologies' Cost of Revenue stood at $23.7 million in 2022, then tumbled by 62.56% to $8.9 million in 2023, then jumped by 142.96% to $21.6 million in 2024, then retreated by 15.53% to $18.2 million in 2025, then gained by 2.66% to $18.7 million in 2026.
• Business Quant data shows ADPT's Cost of Revenue at $18.7 million in Q1 2026, $18.2 million in Q4 2025, and $18.2 million in Q3 2025.